Research graph
References from Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms. Local targets link to admitted publications; unresolved targets remain external evidence.
SOHO state of the art updates and next questions | accelerated phase of MPN: what it is and what to do about it
10.1016/j.clml.2023.01.011 · 2023 · External reference
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia
10.3324/haematol.2023.283950 · 2025 · External reference
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
10.1182/bloodadvances.2024012880 · 2024 · External reference
Genomics of MPN progression
10.1182/hematology.2020000129 · 2020 · External reference
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS
10.1080/17474086.2024.2422554 · 2024 · External reference
Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations
10.1158/1078-0432.ccr-21-3467 · 2022 · External reference
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib
10.1111/bjh.16709 · 2020 · External reference
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors
10.1182/bloodadvances.2020001528 · 2020 · External reference
IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: a multicentre experience
10.1111/bjh.19027 · 2023 · External reference
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
10.1182/blood-2016-08-733196 · 2017 · External reference
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
10.1016/j.leukres.2012.08.013 · 2012 · External reference
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
MIPSS70+ Version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis
10.1200/jco.2018.78.9867 · 2018 · External reference
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
10.1038/s41408-018-0095-2 · 2018 · External reference
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms
10.1182/blood-2018-03-785907 · 2018 · External reference
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes
10.1182/bloodadvances.2018021469 · 2018 · External reference
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
10.1182/bloodadvances.2018015875 · 2018 · External reference
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
10.1002/ajh.24973 · 2018 · External reference
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS
10.1182/bloodadvances.2020002621 · 2020 · External reference
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN
10.1182/bloodadvances.2023011735 · 2024 · External reference
